Search research articles
Contact Us
Filters
Showing results (101-110 of 251) with videos related to
Page
of 26
Sort By:
STAR Protocols
|
October 21, 2022
High-throughput mass cytometry staining for deep phenotyping of human natural killer cells
Amira Ben Amara, Marie-Sarah Rouviere, Stéphane Fattori, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2009
Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia
Gary J Schiller, Susan M O'Brien, Arnaud Pigneux, et al.
Experimental Hematology
|
October 2, 2012
Donor CD3(+) lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: single-center experience
Jean El-Cheikh, Roberto Crocchiolo, Sabine Furst, et al.
Leukemia & Lymphoma
|
February 18, 2016
The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m(2) intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia
Anne Wanquet, Roberto Crocchiolo, Sabine Furst, et al.
Frontiers in Immunology
|
January 27, 2025
CD56<sup>neg</sup> CD16<sup>+</sup> cells represent a distinct mature NK cell subset with altered phenotype and are associated with adverse clinical outcome upon expansion in AML
Julia Wlosik, Florence Orlanducci, Manon Richaud, et al.
Seminars in Arthritis and Rheumatism
|
June 27, 2021
Inflammatory myopathies associated with myelodysplastic syndromes: A French multicenter case control study and literature review
Antoine Briantais, Julie Séguier, Benjamin De Sainte Marie, et al.
International Journal of Oncology
|
May 5, 2005
Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion
Anne Murati, Christine Arnoulet, Marina Lafage-Pochitaloff, et al.
British Journal of Haematology
|
May 8, 2013
A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies
Gert J Ossenkoppele, Bob Lowenberg, Pierre Zachee, et al.
Blood Advances
|
August 19, 2018
Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia
Brian Ball, Rami S Komrokji, Lionel Adès, et al.
British Journal of Haematology
|
June 19, 2012
Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia
Susan O'Brien, David A Rizzieri, Norbert Vey, et al.
Page
of 26
Search research articles
Search
Showing results (101-110 of 251) with videos related to
Sort By:
Page
of 26
STAR Protocols
|
October 21, 2022
High-throughput mass cytometry staining for deep phenotyping of human natural killer cells
Amira Ben Amara, Marie-Sarah Rouviere, Stéphane Fattori, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2009
Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia
Gary J Schiller, Susan M O'Brien, Arnaud Pigneux, et al.
Experimental Hematology
|
October 2, 2012
Donor CD3(+) lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: single-center experience
Jean El-Cheikh, Roberto Crocchiolo, Sabine Furst, et al.
Leukemia & Lymphoma
|
February 18, 2016
The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m(2) intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia
Anne Wanquet, Roberto Crocchiolo, Sabine Furst, et al.
Frontiers in Immunology
|
January 27, 2025
CD56<sup>neg</sup> CD16<sup>+</sup> cells represent a distinct mature NK cell subset with altered phenotype and are associated with adverse clinical outcome upon expansion in AML
Julia Wlosik, Florence Orlanducci, Manon Richaud, et al.
Seminars in Arthritis and Rheumatism
|
June 27, 2021
Inflammatory myopathies associated with myelodysplastic syndromes: A French multicenter case control study and literature review
Antoine Briantais, Julie Séguier, Benjamin De Sainte Marie, et al.
International Journal of Oncology
|
May 5, 2005
Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion
Anne Murati, Christine Arnoulet, Marina Lafage-Pochitaloff, et al.
British Journal of Haematology
|
May 8, 2013
A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies
Gert J Ossenkoppele, Bob Lowenberg, Pierre Zachee, et al.
Blood Advances
|
August 19, 2018
Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia
Brian Ball, Rami S Komrokji, Lionel Adès, et al.
British Journal of Haematology
|
June 19, 2012
Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia
Susan O'Brien, David A Rizzieri, Norbert Vey, et al.
Page
of 26